Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06089824 · ClinicalTrials.gov registry record
Drug Utilisation of Mysimba/Contrave
A clinical trial, sponsored by Currax Pharmaceuticals.
- Completed
- Registry status
- 43,324
- Enrollment target
NCT06089824: Completed study, sponsored by Currax Pharmaceuticals.
NCT06089824 is a clinical trial that has completed, run by Currax Pharmaceuticals. The registered enrollment target is 43,324 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06089824 has completed, sponsored by Currax Pharmaceuticals.
- COMPLETED
- Registry status
- 43,324 participants
- Enrollment target
Study Summary
This study will assess a retrospective cohort of users of Mysimba/Contrave with up to 548 days (\~18 months) after initiation with treatment with Mysimba/Contrave. This study will describe Mysimba/Contrave utilisation and incidence of AESIs for users compliant and non-compliant with the SmPC.
Primary Outcome
Patient demographics (years of age on index date)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43,324 participants |
| Start Date | 2014-09 |
| Est. Completion | 2022-10 |
What the finished NCT06089824 record still lists
NCT06089824 is an observational study that tracks outcomes without assigning an intervention. Its 43,324 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT06089824 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06089824 about?
NCT06089824 is a clinical study titled "Drug Utilisation of Mysimba/Contrave". This study will assess a retrospective cohort of users of Mysimba/Contrave with up to 548 days (\~18 months) after initiation with treatment with Mysimba/Contrave. This study will describe Mysimba/Contrave utilisation and incidence of AESIs for users compliant and non-compliant with the SmPC.
What is the current status of trial NCT06089824?
This trial is currently completed. The enrollment target is 43,324 participants. The study started on 2014-09. Estimated completion is 2022-10.
Who is sponsoring clinical trial NCT06089824?
This trial is sponsored by Currax Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05607732 · 45,257 participants · NA
Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial
- NCT06824350 · 45,450 participants · NA
Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates
- NCT06597968 · 45,991 participants
Evaluating the Real World Performance of an AI Based Lung Nodule Detection Tool
- NCT01255748 · 40,000 participants
Registry Study for Radiation Therapy Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia